Rani Therapeutics (RANI) News Today

Rani Therapeutics Holdings, Inc. (RANI) — Shares have moved higher today after a wave of bullish analyst notes, a major partner deal and heavy bullish options activity. Investors appear to be pricing in the commercial partnership with Chugai, fresh financing and upgraded price targets.

• Positive Sentiment: HC Wainwright reaffirmed a "buy" and set an $11.00 price target (implies large upside vs. the current price), reinforcing analyst optimism. HC Wainwright Reaffirms Buy Rating for Rani Therapeutics (NASDAQ:RANI)
• Positive Sentiment: Maxim Group raised its price target to $10 (from $5) and reiterated a buy, adding further upward pressure from the sell‑side. Maxim Group Issues Positive Forecast for Rani Therapeutics (NASDAQ:RANI) Stock Price
• Positive Sentiment: Analysts at Seeking Alpha initiated coverage at Buy, citing the landmark Chugai collaboration (~$1.085B scope), positive preclinical R&D (RT‑114) and an oversubscribed $60.3M private placement that extends runway into 2028 — fundamental catalysts that support higher valuation. Rani Therapeutics: Initiating At Buy On Promising RaniPill Advancement With Chugai
• Positive Sentiment: Unusually large options activity — ~37,490 call options bought in one day (4,337% above average) — signals speculative bullish positioning that can amplify short‑term upside. Rani Therapeutics Target of Unusually Large Options Trading (NASDAQ:RANI)
• Neutral Sentiment: MarketBeat notes the consensus across five analysts is an average "Moderate Buy" (four buys, one sell) — broadly positive but not unanimous. Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Average Rating of "Moderate Buy" by Analysts
• Negative Sentiment: High volatility and heavy retail/options flow have produced dramatic price swings (recent multi‑day surge tied to the Chugai deal); this raises the risk of sharp pullbacks and speculative squeezes — investors should be aware of execution and commercialization risks despite the positive headlines. Rani Therapeutics (RANI): Examining Valuation After Landmark Chugai Deal and $60M Funding Boost

Bottom line for investors: bullish analyst upgrades, the Chugai collaboration and strong options buying are driving today’s upside, but the move is highly news‑driven and volatile—suitable for investors who can tolerate event‑driven risk.